Brown Fat and Muscle Metabolic, Differential Diagnosis
Conditions
Keywords
Psychological, Comprehensive treatment, Positron emission computed tomography/Magnetic resonance
Brief summary
False positives for Brown Fat & Muscle（F&M） always affect the evaluation of metabolic disease treatment. Recently, using PET/CT，international journals such as Journal of Nuclear Medicine reported that the amount of active brown fat was correlated with renal creatinine clearance and subject to regulation by atrial natriuretic peptide in addition to association of season and temperature. At present，studies based on PET/CT have shown that elimination of the above factors, brown fat(even muscle) will still appear false positive metabolism in tumor patients. In view of the basis of Positron emission computed tomography/Magnetic resonance (PET/MRI) brain function research，our team speculate that it may be related to psychological or cortex metabolism. And there is a lack of studies on the correlation between the psychosocial，cortex structure and metabolism. Therefore, it suggests that，combination of structure and metabolism，PET/MRI will play a role in studying the effects of psychological on F&M false-positive metabolism in malignant patients. In this project, the investigators intend to observe the changes of F&M metabolism with psychological and cortex metabolism after comprehensive treatment in malignant patient by combining PET/MRI. The relationship between F&M metabolism and psychological will be deeply analyzed to provide scientific basis for the development of the differential diagnosis and assessment.
Interventions
OTHERComprehensive treatment of tumor
According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
Sponsors
Tang-Du Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Clinical diagnosis of malignant tumor * Have not yet been receiving comprehensive treatment and should begin within one month * Fasting glucose of diabetic patients is controlled below 11.1 mmol/L. Inclusion Criteria for Healthy Control Participants: • Clinical diagnosis of Healthy Control
Exclusion criteria
* Fasting glucose ≥11.1mmol/L * History of endocrine disease (such as chronic glomerulonephritis, Addison's disease) * Neurological signs and/or history of neurological disease * Have begun comprehensive treatment * Presence of magnetically active objects in the body * Claustrophobia or any other medical condition that would preclude the participant from lying in the PET/MRI scanner for approximately 40 mins.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change metabolism of glucose of M&F | Baseline, 1 day ( Contrast scanning) | Glucose metabolic scores will be assessed with visual scale |
| Change of the glucose metabolism area of M&F | Baseline, 1 day ( Contrast scanning) | Five different anatomical locations (subphrenic, paravertebral, mediastinal, cervical, supraclavicular) will be assessed with visual. |
| Change of activated M&F volume | Baseline, 1 day ( Contrast scanning) | Activated M&F volume before and after comprehensive treatment were evaluated by post-processing software |
| Change of M&F SUVmax and SUVmean | Baseline, 1 day ( Contrast scanning) | SUVmax and SUVmean scores will be measured by post-processing software. |
| Change of anxiety symptoms | Baseline, 1 day ( Contrast scanning) | Anxiety symptoms scores will be assessed with Hamilton Anxiety Scale. |
| Change of sleep | Baseline, 1 day ( Contrast scanning) | Sleep scores will be assessed with Pittsburgh sleep quality index one month before scanning |
| Change of metabolism of glucose in the M&F | Baseline, 1 day ( Contrast scanning) | Accumulation of 18F-FDG will be analyzed by treatment-related, psychology-related and intervention-related Positron emission tomography/ Magnetic resonance |
Countries
China
Contacts
Primary ContactLi Yunbo, MD
Backup ContactYuan Menghui, PHD
Outcome results
None listed